Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel R. Faga
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 104
- Beta
- 3.37
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 54.84
Financials
TRAX has only 5 quarterly periods on file — the charts below show the full history available.
Net Income
$-31.36MEBITDA
$-31.85MFree Cash Flow
$-17.05MEPS (diluted)
$-0.88Shares Outstanding (diluted)
35.75M+2.9%Operating Expenses
$32.84MCash & Debt
$155.63MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-166.09M | $0.00 |
| 2024 | $0.00 | $-163.71M | $0.00 |
| 2023 | $0.00 | $-106.15M | $-3.05 |
Valuation
TRAXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
170+142.86%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·19d ago·Positive
First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the third quarter ended Sept. 30, 2026, and provided a business update.
View source ↗ - Newsglobenewswire.com·19d ago·Positive
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:
View source ↗ - Newsseekingalpha.com·39d ago·Neutral
…ffers a differentiated CD122 antagonist, ANB033, showing promising Phase 1b data in celiac disease with statistically significant histology and symptom improvements. TRAX's ANB033 demonstrated a stronger efficacy signal versus Teva's IL-15 inhibitor, with a more pronounced reduction in mucosal injury and symptom severity under a harsher gluten challenge. With $168M in cash and a projected runway into Q2 2028, TRAX is positioned for late-stage celiac trials and expansion into two additional indic…
View source ↗ - Newsmarketbeat.com·41d ago·Neutral
First Tracks' ANB033 Clears Key Phase Ib Celiac Disease Study Goals First Tracks Biotherapeutics NASDAQ: TRAX reported top-line results from the first cohort of its Phase Ib study of ANB033 in celiac disease, saying the investigational CD122 antagonist met histologic and symptom-related objectives during a placebo-controlled gluten challenge.
View source ↗ - Newsglobenewswire.com·42d ago·Positive
…e 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026 SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b tri…
View source ↗ - Newsglobenewswire.com·88d ago·Positive
First Tracks Biotherapeutics Announces Participation in September Investor Conferences SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:
View source ↗ - Newsbenzinga.com·101d ago·Negative
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results First Tracks Biotherapeutics Inc (NASDAQ:TRAX) reported a narrower loss for the second quarter on Wednesday.
View source ↗ - Newsglobenewswire.com·102d ago·Positive
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.
View source ↗
Earnings
Tue, Feb 2(in 2 months)
Consensus estimate $-0.73 per share
Typical surprise -18.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$-0.88 vs $-0.90beat
- Wed, Aug 12$-0.95 vs $-0.80miss
- Thu, May 14$-1.45 vs $-0.98miss
Estimates and results for TRAX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TRAX officers and directors.
- Bought
- —
- Sold
- $1.8m
0 trades
1 trade
- Ware J. Anthonysold
20 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TRAX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
